Fecal Transplants Cut Alcohol Cravings in 9 of 10 Patients, Study Review Finds

Standard medications for alcohol use disorder (AUD) fail more often than they work: even with approved drugs like naltrexone, acamprosate, and disulfiram, relapse rates exceed 60%. A new systematic review pulls together eleven clinical trials that tried a different lever entirely, the gut microbiome (the community of bacteria living in the intestines) and the hormones it talks to the brain through, and finds real signals of benefit alongside real limits. If you or someone you know is managing AUD, or the liver damage that often comes with it, here is what the actual data shows and does not show.

Key takeaways:

• In a small double-blind trial, a fecal microbiota transplant (FMT, transferring stool bacteria from a screened healthy donor) reduced alcohol craving in 9 of 10 patients with alcohol-associated cirrhosis, versus 3 of 10 on placebo (p = 0.02).
• Across five trials of GLP-1 drugs (the same drug class as Ozempic and Wegovy), three found reduced alcohol use, while two showed the same direction of effect without reaching statistical significance.
• The review pooled 779 participants across 11 small trials, sample sizes 16 to 151 each, evidence its own authors call promising but not yet proof.
• None of these interventions is an approved or recommended treatment for alcohol use disorder outside a clinical trial.

Fecal Microbiota Transplant Cut Alcohol Craving and Inflammation

In the most tightly controlled trial the review covers, a double-blind, randomized study gave 20 patients with alcohol-associated cirrhosis either a single FMT enema from a screened donor or a placebo. By day 15, craving had dropped in 9 of 10 patients who received FMT compared with 3 of 10 on placebo (p = 0.02), alongside a drop in a urine marker of recent drinking. The FMT group also showed higher microbial diversity, more of the short-chain-fatty-acid-producing bacteria called Ruminococcaceae, and lower blood levels of the inflammatory marker IL-6 and LBP (lipopolysaccharide-binding protein, a marker of bacteria leaking from the gut into the bloodstream). Over six months, serious AUD-related medical events were less frequent in the FMT group (1 versus 7 cases, p = 0.02), though the difference in long-term abstinence, 3 of 10 versus 1 of 10, did not reach statistical significance in a group this small.

Alcohol-Associated Liver Disease Patients Saw the Clearest Benefit

The clearest, most consistent results in the whole review came from patients who already have alcohol-associated liver disease (ALD), meaning liver damage from drinking severe enough to be diagnosed on its own, a group covered by three of the eleven studies. In a retrospective study of 61 men with severe alcoholic hepatitis who had already failed or could not tolerate corticosteroids (the standard treatment), those given FMT instead of standard care relapsed less often (28.6% versus 53.8%, p = 0.04) and took nearly twice as long to relapse when they did (a median of 436 days versus 197 days, p = 0.002). Three-year survival favored the FMT group too, at 65.7%, though that difference landed just short of standard statistical significance (p = 0.052). For patients managing both AUD and liver disease, especially anyone who has already tried and failed steroid treatment for alcoholic hepatitis, this is the strongest signal in the review.

How Researchers Narrowed 853 Studies Down to Eleven

The review, whose funding included the National Institute on Alcohol Abuse and Alcoholism (NIAAA), searched PubMed, Google Scholar, Scopus, and ClinicalTrials.gov through July 2026 and screened 853 initial records down to eleven clinical trials that tested a gut-microbiome or gut-hormone intervention in people with AUD. Together those trials covered 779 participants, with individual trial sizes ranging from 16 to 151 people and ages spanning 24 to 67 years. Five of the eleven trials specifically measured gut dysbiosis (an imbalance in the normal mix of gut bacteria) in their AUD patients before treatment, which is the biological rationale for targeting the gut in the first place: chronic heavy drinking damages the intestinal lining, letting bacterial toxins and inflammatory signals leak into the bloodstream and, from there, potentially the brain.

What This Means If You Are Managing Alcohol Use Disorder

None of the treatments in this review, including FMT, is an approved therapy for AUD, and attempting a do-it-yourself fecal transplant is genuinely dangerous; every trial here used a clinically screened donor and medical supervision. That said, the review gives two things worth raising with a doctor. First, if you already have a qualifying condition like obesity, it may be worth asking about GLP-1 drugs (semaglutide and its relatives, studied for alcohol use disorder in patients with comorbid obesity), since three of five trials in this review tied the drug class to reduced drinking, including one 26-week trial where semaglutide cut heavy drinking days by 41.1% compared with 26.4% on placebo (p = 0.015). Second, if you or a family member has alcohol-associated liver disease that has not responded to standard treatment, it is reasonable to ask whether an FMT clinical trial is enrolling nearby, since that is where the review found its most durable benefit. A daily fiber supplement called inulin, tested at 8 grams a day for three weeks, did not reduce relapse rates but was linked to a measurable rise in a brain-growth factor called BDNF and to improved sociability, an effect worth knowing about even though it fell short of changing drinking itself.

Why the Evidence Still Falls Short of Proof

The review's own authors are explicit that the "magnitude and consistency" of benefit varied considerably from trial to trial, and most of these studies were small enough that a handful of participants could swing the result either way. The inulin trial found no significant effect on relapse (48% versus 32% of participants relapsed by week two, not a statistically meaningful gap) despite the positive BDNF finding. A phase 1b trial of the ghrelin receptor blocker PF-5190457, in just 11 participants, found no effect on inflammation markers at all, undercutting ghrelin as a therapeutic target for now. And two of the five GLP-1 trials, including a 127-person exenatide study, found no statistically significant reduction in drinking despite pointing the same direction as the positive results.

Large, Controlled Trials Are the Next Step

The review's authors call for larger, controlled trials to confirm which gut-brain interventions actually change drinking outcomes, and to work out dosing, timing, and which patients benefit most, singling out the ghrelin and GLP-1 hormone pathways as mechanistically promising but still under-tested specifically for AUD. No firm timeline is given, but the pharmaceutical side already appears ahead of the microbiome-transplant side: multiple GLP-1 trials for AUD, including large placebo-controlled studies, have already reported results, while FMT for AUD remains confined to small pilot-scale trials like the 20-person study described above.

Common Questions

Can I try a fecal transplant at home for a drinking problem? No. Every FMT trial in this review used stool from a medically screened donor, delivered by a clinician in a controlled setting; unsupervised FMT carries a real risk of transmitting infection.

Does Ozempic or Wegovy treat alcohol use disorder? Semaglutide, the active drug in Ozempic and Wegovy, is not approved for AUD. Three of five GLP-1 trials in this review found it reduced alcohol use, but two others found no statistically significant effect, so the evidence is directionally positive but still mixed.

What is gut dysbiosis? Gut dysbiosis is an imbalance in the normal mix of bacteria living in the intestines. Five of the eleven studies in this review measured it as a feature of alcohol use disorder before treatment began.

How many people were studied? This was a systematic review pooling eleven separate clinical trials with 779 total participants; it did not run a new trial of its own, so the numbers above come from combining previously published studies.

References

1. Prabha Bhandari, Abdelhaleem Sideeg, Mohamed Elfeki, Chencheng Xie, Ashwani K. Singal (2026). Therapeutic modulation of the gut-brain axis in alcohol use disorder: A systematic review. Metabolism Open. https://doi.org/10.1016/j.metop.2026.100495
2. Jasmohan S. Bajaj, Edith A. Gavis, Andrew Fagan, et al. (2021). A Randomized Clinical Trial of Fecal Microbiota Transplant for Alcohol Use Disorder. Hepatology. https://doi.org/10.1002/hep.31496
3. Apurva Pande, Shvetank Sharma, Vikas Khillan, et al. (2022). Fecal microbiota transplantation compared with prednisolone in severe alcoholic hepatitis patients: a randomized trial. Hepatology International. https://doi.org/10.1007/s12072-022-10438-0